Chinese study: no benefit for CCRT during IMRT for elderly patients with NPC

  • Oral Oncol

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A retrospective study presents outcomes of intensity-modulated radiotherapy (IMRT) in elderly patients with nasopharyngeal carcinoma (NPC) and suggests that concurrent chemoradiotherapy (CCRT) does not improve survival.

Why this matters

  • The benefits of IMRT and CCRT in elderly patients with NPC are unclear.

Key results

  • 3.5% of patients experienced grade 4 acute leukopenia, 3.5% experienced grade 4 acute neutropenia, and 2.0% experienced grade 4 acute thrombocytopenia; there were no grade 4 late toxicities.
  • Charlson comorbidity index (HR, 0.176; P=.007) was associated with 5-year locoregional recurrence-free survival (LRRFS) in multivariate analysis.
  • T and N stage were associated with 5-year distant metastasis-free survival (DMFS; HR, 1.538 [P=.036] and 1.794 [P=.005], respectively), disease-specific survival (DSS; HR, 1.552 [P=.021] and 1.854 [P=.009], respectively), and OS (HR, 1.571 [P=.001] and 1.622 [P=.001], respectively) in multivariate analysis.
  • Patients who received RT alone vs CCRT had similar LRRFS (94.0% vs 92.2%; P=.463), DMFS (83.5% vs 86.2%; P=.278), DSS (81.8% vs 83.1%; P=.384), and OS (74.0% vs 72.8%; P=.542).

Study design

  • 254 patients aged ≥60 years with nonmetastatic NPC who underwent IMRT were analyzed for outcomes.
  • Funding: Science and Technology Project of Guangdong Province; Wu Jieping Medical Foundation.

Limitations

  • Retrospective study.